(Total Views: 241)
Posted On: 07/12/2018 10:22:30 AM
Post# of 72443
Re: lousy.engineer #47317
You are smearing Mr. Ehrlich by claiming that because a long time he briefly, and let me emphasize BRIEFLY, worked at a company that failed, he is somehow responsible -- because your premise was "IF NNVC failed, will IPIX fail too?"
You have come here at various times, and when you have posted it is often to try to stir up a food fight by, for instance, reposting LIES from another website.
We now are certain of your agenda. No honest person would say that because someone left a company, evidently angrily, 10 years ago, and then than mismanaged company finally failed, that someone's current company might end up the same way.
Your agenda is clear -- smear the CEO, smear the company.
You posted your garbage, we are not so stupid as to fail to see what you are doing.
My other point is this -- if Mr. Ehrlich HAD stayed and had been allowed to guide NNVC the way he has guided IPIX, I am confident that it would not have returned zero to shareholders, never having even attempted a clinical trial. Mr. Ehrlich would have either gotten one of their purported drugs to clinical trial, or acknowledged that the drug was not worthy of one -- and would have saved shareholders millions of dollars of losses.
Lousy Engineer, we have your number.
You have come here at various times, and when you have posted it is often to try to stir up a food fight by, for instance, reposting LIES from another website.
We now are certain of your agenda. No honest person would say that because someone left a company, evidently angrily, 10 years ago, and then than mismanaged company finally failed, that someone's current company might end up the same way.
Your agenda is clear -- smear the CEO, smear the company.
You posted your garbage, we are not so stupid as to fail to see what you are doing.
My other point is this -- if Mr. Ehrlich HAD stayed and had been allowed to guide NNVC the way he has guided IPIX, I am confident that it would not have returned zero to shareholders, never having even attempted a clinical trial. Mr. Ehrlich would have either gotten one of their purported drugs to clinical trial, or acknowledged that the drug was not worthy of one -- and would have saved shareholders millions of dollars of losses.
Lousy Engineer, we have your number.
(10)
(0)
Scroll down for more posts ▼